slobbermutt, metformin has always been known to be dangerous to the liver, pancreas, and kidneys with plenty of other side effects too. However for type 2s who would not use injected prandial insulin and/or injected basal insulin, it was the least bad choice for type 2s to try to bring blood sugars down. Many doctors know metformin puts many type 2s on the road to becoming type 1s.
apomyster, it is difficult to imagine taking all those drugs each day or week. I just know I would refuse to do it unless I saw some improvement in my blood glucose. Metformin is surely not doing your liver or pancreas any good.
regenmedprovider, you can split your post into multiple parts if you wish.
brian12372, I just reviewed your posts since you started on Afrezza around February 3rd. You don't post often, but what you do post indicates to me you are having very good to great success with Afrezza. Is that right? Would you say you are a very satisfied customer?
jhall5197, of the type 2s you see each day, what percent do you consider very overweight, i.e., not just overweight?
Can't you provide better clues than that? I am an investor, and my car still has hubcaps. It says I have to signup to get information. Too bad I won't signup.
bmcgoo_03, Afrezza is not only a step function increase in productivity for diabetics, but also offers them far more than a step function improvement in physiological chemical control within desired blood glucose limits to prevent organ and nerve damage. If your premise about endocrinologists is correct, they are still supposed to do no harm. If Afrezza will benefit their patients over and above injected prandial insulins, they will prescribe Afrezza and have more time for other endocrine glands. Right? They have had to spend lots of their time and efforts on diabetes, because there are so many of them who have had to use roller coaster insulin. With Afrezza prandial insulin they will be able to concentrate more on all the other endocrine diseases that have not gotten as much of their attention in the past.
pharmerboy87, I agree with you. I just think you omitted the orals which doctors have prescribed first before putting the type 2s on insulin as you indicate above. My post on this you will find embedded in this link.
badbart3, I agree Afrezza as first line treatment for type 2 diabetics is coming. I suggested to doctor.stockpicker to think about this back in October 2014. Also Al Mann in an interview in October 2013 said orals for type 2s were prescribed, because there was not a good prandial insulin. Well now we have a good prandial insulin. You will find my post about it embedded in this Yahoo link below. I tried to shorten the link, but Yahoo would not post it.
badbert3, I appreciate your posting this, but where is the case history quote lifted from? Who or what published this information and when?
watjnj, when you sign the margin agreement, it is incorporated in that agreement. If you really had a taxable account that was also a cash account, you would need to negotiate before you converted to a margin account (and actually Not convert to a margin account). If you have some kind of IRA type account, those are cash accounts and you can get interest for letting Fidelity loan out those shares.
watjnj, if you really did that, Fidelity already can loan them already. You will get no money/interest for that. Good luck staying out of traffic.
drionache, is this your original post?
launch is very smart. all preparation are in place: spirometer reps, ICD codes to bill for spirometry available, code for billing for patients with needle fobia. most insurances have afreza on formularies
limited samples. each doctor given 3-6 samples then sanofi follows up if they will write prescriptions.
one endocrinologist is already on afrezza and he is very happy.
TV commercials will start in July after target doctors will be educated by the reps. they have a list of target doctors.
GS knew all this info before me and probably are buying shares now. number of prescriptions should be low now because few samples available.
i got my demo inhaler, very small
afrezzauser may be a speaker for sanofi.
i am very excited and patient.
drug reps and doctors are very excited also
centralcoastinvestor, doctor.stockpicker wrote about ACCORD about a month ago, and you can find his input at this url down the page. I would just add that instead of lead, his post should read led. It changes the meaning to what I am sure he meant.
mswrichmond, you have been quiet since your Sanonfi rep meeting last month where you loaded up with Afrezza samples and copay cards. How has it been going for you and your patients now that you have some of them on Afrezza, and you have likely been able to follow-up.
rmerritt33, I think doctors will start to get feedback in June 2015 instead of September as you forecast. The reason I think is the ADA scientific sessions in June in Boston. I feel sure there will be some papers presented at such a forum with some Afrezza studies or preliminary study data on various figures of merit, including A1c. The word will start getting out there, because diabetes researchers will be talking about what they are seeing in their labs and studies.
The Sanofi R&D guy normally does not say much about Afrezza, but now that Sanofi has launched Afrezza he might say more. It's a positive if he says more, but should he do his normal routine and say very little about Afrezza it is sort of neutral imo.
avi8torsic, are you aware when you lift text from someone's publication you should put it in quotes or at least reference it? I recognize the post above is not your own work, but why confuse people who might think it is your work.